Galvanize Therapeutics key facts
as of Oct 2026- Developer of energy-based medical device technology designed to improve biological processes.
- Galvanize Therapeutics is valued at approximately $300.0M as of Oct 2026 (last reported valuation).
- It has raised $206.1M across 4 recorded rounds; the latest was Later Stage VC (Series C) ($100.0M) in Jul 2025.
- Notable investors include Fidelity Management & Research Company, Norwest, Sofinnova Partners, T. Rowe Price Group, Perceptive Advisors — 13 tracked in total.
- 3 institutional filers report fund marks on Galvanize Therapeutics across 59 filings.
- Galvanize Therapeutics has filed 5 Form Ds with the SEC since 2020, most recently Sep 2025 ($96.1M sold to 28 investors).
- Status: Privately Held (backing).
Galvanize Therapeutics's last reported valuation, Mar 2022. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Galvanize Therapeutics: the Monday email on marks, rounds and moves
Institutional fund marks on Galvanize Therapeutics
3 filers · latest Jul 20263 SEC-registered funds reported 59 fair-value marks on Galvanize Therapeutics between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Galvanize Therapeutics funding rounds
4 roundsWho backs Galvanize Therapeutics
13+Galvanize Therapeutics valuation
Galvanize Therapeutics's last reported valuation was $300 million in Mar 2022. No priced round, secondary trade or fund mark has surfaced since.
Recent activity
In the last 90 days, Galvanize Therapeutics's record added 3 institutional fund marks (latest period Jul 2026).
How much has Galvanize Therapeutics raised?
Galvanize Therapeutics has raised $206 million across 4 recorded rounds since 2020. The largest was a $6.1 million early-stage round in Mar 2020; the most recent was a $100 million Series C in Jul 2025.
Galvanize Therapeutics has filed 5 Form Ds with the SEC since 2020, most recently in Sep 2025 ($96.1 million sold to 28 investors).
Institutional holders and vehicles
3 SEC-registered funds reported 59 fair-value marks on Galvanize Therapeutics between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Galvanize Therapeutics investors
13 investors are on record for Galvanize Therapeutics, including Fidelity Management & Research Company, Norwest, Sofinnova Partners and T. Rowe Price Group. The Series C in Jul 2025 drew 11 investors.
Comparable companies
Comparable therapeutic devices names by valuation on PrivateMarketView: Saluda Medical ($435 million), LightForce ($400 million) and Soufflé Therapeutics ($345 million).
About Galvanize Therapeutics
Developer of energy-based medical device technology designed to improve biological processes. The company's tool utilizes short-duration and high-voltage electrical pulses to create an electric field that destabilizes cells through multiple biochemical processes, enabling medical professionals to deliver improved healthcare services to patients.
- Industry
- Therapeutic Devices
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2015
- Employees
- 134
- Website
- galvanizetx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.